Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40

Guggenheim analyst Michael Schmitz has maintained a Buy rating on BlossomHill Therapeutics (NASDAQ: BLSM) and increased the price target from $30 to $40.